New Delhi: The Delhi High Court on Friday (June 4) expressed anguish over the implementation of the Centre’s COVID 19 vaccination policy. The observation came when it was hearing an issue related to the manufacturing of COVID-19 vaccine Sputnik V by India’s Panacea Biotec in collaboration with the Russian Direct Investment Fund (RDIF).
The High Court directed the Centre to release an arbitral award of over ₹ 14 crores along with interest from 2012 to the company so that it can begin the vaccine manufacturing at the earliest if it gets the approval to do so from the government.
The bench of Justices Manmohan and Najmi Waziri said, “Today, we are a bit anguished with the way things have transpired during the second wave. As a responsible citizen, you also would be anguished. Vaccine shortage is hitting each and every one. Even today vaccine is not available in Delhi. You have good products in India, a little handholding will work”.
“Someone from Russia was able to locate infrastructure in Himachal Pradesh but the Centre has failed to do so,” it added.
Panacea Biotec had approached the High Court seeking to modify an order that was passed in July 2020 in relation to an arbitral award, running into crores of rupees, passed in its favour.
The company was demanding the arbitral funds and the interests rate from 2012 to be released so that it could quickly start the manufacturing of Sputnik V vaccines.